Spanogiannopoulos Peter, Bess Elizabeth N, Carmody Rachel N, Turnbaugh Peter J
Department of Microbiology &Immunology, George Williams Hooper Foundation, University of California San Francisco, 513 Parnassus Avenue, San Francisco, California 94143, USA.
Nat Rev Microbiol. 2016 Apr;14(5):273-87. doi: 10.1038/nrmicro.2016.17. Epub 2016 Mar 14.
Although the importance of human genetic polymorphisms in therapeutic outcomes is well established, the role of our 'second genome' (the microbiome) has been largely overlooked. In this Review, we highlight recent studies that have shed light on the mechanisms that link the human gut microbiome to the efficacy and toxicity of xenobiotics, including drugs, dietary compounds and environmental toxins. Continued progress in this area could enable more precise tools for predicting patient responses and for the development of a new generation of therapeutics based on, or targeted at, the gut microbiome. Indeed, the admirable goal of precision medicine may require us to first understand the microbial pharmacists within.
尽管人类基因多态性在治疗结果中的重要性已得到充分证实,但我们的“第二基因组”(微生物组)的作用在很大程度上被忽视了。在本综述中,我们重点介绍了最近的一些研究,这些研究揭示了将人类肠道微生物组与异生物素(包括药物、膳食化合物和环境毒素)的功效及毒性联系起来的机制。该领域的持续进展可能会催生更精确的工具,用于预测患者反应以及开发基于肠道微生物组或针对肠道微生物组的新一代疗法。事实上,精准医学这一令人钦佩的目标可能要求我们首先了解体内的微生物“药剂师”。